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Target specificity of mammalian DNA methylation and 
demethylation machinery 
M. Ravichandrana, R. Z. Jurkowskab,† and T. P. Jurkowskic,† 
DNA methylation is an essential epigenetic modification for mammalian embryonic development and biology. DNA 
methylation pattern across the genome, together with other epigenetic signals, is responsible for the transcriptional profile 
of the cell and thus preservation of the cell’s identity. Equally, the family of TET enzymes which triggers the initiation of the 
DNA demethylation cycle plays a vital role in the early embryonic development and lack of these enzymes at later stages 
leads to diseased state and dysregulation of the epigenome. DNA methylation has long been considered a very stable 
modification, however, it has become increasingly clear that for the establishment and maintenance of the methylation 
pattern both, generation of DNA methylation and its removal are important, and that a delicate balance of ongoing DNA 
methylation and demethylation shapes the final epigenetic methylation pattern of the cell. Although this epigenetic mark 
has been investigated in great detail, it still remains to be fully understood how specific DNA methylation imprints are 
precisely generated, maintained, read or erased in the genome. Here, we provide a biochemist’s view on how both DNA 
methyltransferases and TET enzymes are recruited to specific genomic loci, and how their chromatin interactions, as well as 
their intrinsic sequence specificities and molecular mechanisms contribute to the methylation pattern of the cell.  
A Introduction 
Modification of DNA in CpG dinucleotides plays an important role in 
mammalian development and has been studied for decades. Yet, 
despite breakthroughs in high-resolution mapping of the distribution 
of DNA methylation across mammalian genomes and progress in 
understanding the targeting and regulation of DNA 
methyltransferases in cells, it remains not fully known how specific 
methylation patterns are precisely generated, maintained, read and 
erased. Similarly, although the contribution of DNA methylation to 
human diseases, especially cancer, has been clearly demonstrated in 
numerous studies, the exact molecular mechanisms leading to the 
aberrant methylation patterns generation are not yet fully 
elucidated. The recent discovery of TET enzymes showed that DNA 
demethylation can occur through stepwise oxidation of 5-
methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), 5-
formylcytosine (5fC) and finally to 5-carboxylcytosine (5caC,) 
followed by the removal of the higher oxidized bases by Thymine 
DNA glycosylase (TDG) and base excision repair mechanism. Genetic 
studies revealed that TET proteins are involved in numerous 
biological processes, such as transcriptional regulation, 
hematopoietic stem cell differentiation, embryonic, and primordial 
germ cells (PGCs) development, and that these enzymes are 
commonly deregulated in cancer. While the biological functions of 
TET enzymes have been studied extensively, very little is known 
about their biochemical properties. Here, much more work is needed 
to understand the specificity and catalytic mechanism of TET 
proteins, as well as the contribution of different domains to enzymes 
targeting and regulation. Importantly, novel regulatory mechanisms, 
including allosteric regulation by protein domains and other protein 
partners or influence of cofactor molecules (like vitamin C) have been 
described recently for DNMTs and TET enzymes, respectively, 
providing another layer of complexity in the regulation of these 
fascinating proteins. In this review, we summarise the most 
important properties of both DNA methyltransferases and TET 
enzymes and dissect molecular pathways leading to their 
recruitment to the target sites.  
A Setting DNA methylation 
Methylation of mammalian DNA at CpG sites was identified in the 
beginning of the 1980s1, 2 followed by the discovery of the first 
mammalian DNA methyltransferase (MTase), today called DNMT13, 
4. The other two enzymes, DNMT3A and DNMT3B were identified in 
19985. Surprisingly, a rodent methyltransferase family has recently 
been extended by another member, DNMT3C6. Since their discovery, 
mammalian DNMT enzymes have been intensively investigated and 
pivotal genetic, biochemical, structural and functional studies have 
contributed to the elucidation of enzymatic properties of these 
interesting enzymes, as well as their targeting mechanisms in the 
cells. 
B Mammalian DNA methyltransferases 
DNA methylation is introduced during early stages of mammalian 
development and during maturation of germ cells by two related 
DNA methyltransferases, DNMT3A and DNMT3B, with the help of the 
stimulatory factor DNMT3L7. The methyl group is set at the C5 
position of the cytosine residues, primarily in the CpG dinucleotides. 
However, only certain CpG sites are methylated, thereby generating 
a tissue and cell type-specific patterns of methylation. After their 
establishment, DNA methylation patterns are preserved, with small 
tissue-specific changes. During DNA replication, new unmethylated 
DNA strands are synthesized, leading to the conversion of fully 
methylated CpG sites into hemimethylated sites that are then re-
methylated by a maintenance methyltransferase DNMT1, which 
works essentially as a molecular copy machine8, 9. This elegant 
inheritance mechanism enables DNA methylation function as a main 
epigenetic mark mediating long-term transcriptional silencing. In this 
respect, DNA methylation is involved in silencing of repetitive 
elements, genomic imprinting, X-chromosome inactivation and 
regulation of gene expression during development and cellular 
specialization (reviewed in10, 11). Considering its important biological 
roles, it is not surprising that aberrant DNA methylation changes are 
associated with human diseases12-15 and that DNA methyltransferase 
among other epigenetic factors are attractive therapeutic targets16, 
17. 
B Structural organization of DNA methyltransferases 
In the general architecture of mammalian DNA methyltransferases, 
two functional parts can be distinguished, a large N-terminal 
2 
 
regulatory part and a smaller catalytic domain residing at the protein 
C-terminus (Figure 1)18-20. The N-terminal parts of DNMTs, which 
differ between DNMT1 and DNMT3 enzymes, contain several 
domains with regulatory and targeting functions. They guide the 
nuclear localization of the methyltransferases and mediate their 
interaction with chromatin and other proteins. The C-terminal 
domains harboring the catalytic centers are required for binding of 
the cofactor S-adenosyl-L-methionine (AdoMet) and DNA substrate, 
and for catalysis. C-terminal domains contain several amino acid 
motifs conserved among prokaryotic and eukaryotic C5 DNA 
methyltransferases and fold into a conserved structure called 
AdoMet-dependent MTase fold, characteristic for all DNA-(cytosine-
C5) methyltransferase families. Interestingly, recent structural and 
biochemical studies revealed that the arrangement of the particular 
domains in DNMTs that can be influenced by posttranslational 
modifications and protein partners, plays a critical role in the 
regulation of enzymes’ activity and specificity (reviewed in21). 
C Domain composition of DNMT1 
DNMT1 is a large protein containing several functional domains 
located in its N-terminal part that is linked to the catalytic part by a 
flexible linker composed of lysine-glycine (KG) repeats (Figure 1). The 
DMAP1 (DNA methyltransferase-associated protein 1) interaction 
domain that is located at the very N-terminus of DNMT1, is involved 
in the targeting of Dnmt1 to replication foci22. It is followed by the 
PCNA (proliferating cell nuclear antigen) binding domain (PBD) that 
contributes to the recruitment of DNMT1 to the replication fork 
during S phase. The interaction with PCNA supports efficient DNA 
methylation in the cell23, 24. The third domain involved in the 
targeting of DNMT1 to replication foci25 and to centromeric 
chromatin26 is the replication foci-targeting domain (RFTD). This 
domain is followed by the CXXC domain, which binds unmethylated 
DNA and might contribute to the specificity of DNMT127-29, but its 
exact role in enzyme’s function is still controversial. Finally, the BAH1 
and BAH2 (bromo-adjacent homology 1 and 2) domains located at 
the end of the N-terminal part of DNMT1 are necessary for the 
folding of the enzyme, but their molecular function awaits 
elucidation. Despite presence of all conserved catalytic motifs 
required for catalysis, the isolated catalytic domain of DNMT1 is 
inactive30, 31, suggesting that it is controlled by the N-terminal 
domain of the enzyme. Indeed, structural and biochemical studies 
demonstrated that various domains in the N-terminal part of DNMT1 
surround and contact the catalytic domain27, 32-34, providing first 
understanding of the allosteric regulation of DNMT1 (reviewed in21). 
C Domain composition of DNMT3s family 
The DNMT3 family comprises four members: DNMT3A, DNMT3B and 
DNMT3C (only in rodents), which are enzymatically active, and 
DNMT3L, which does not possess methyltransferase activity, but 
works as a stimulatory factor of DNMT3A and DNMT3B. DNMT3C, 
which has been identified only recently, is a male germline-specific 
variant that arose from duplication of the DNMT3B gene and is 
required for retrotransposon methylation during mouse 
spermatogenesis6. Its orthologue has however not been identified in 
humans. All DNMT3 proteins share considerable sequence similarity 
(Figure 1). In their N-terminal part, two functional domains are 
present, the ADD (ATRX-DNMT3-DNMT3L) domain and the PWWP 
domain, which is absent in DNMT3L and DNMT3C. 
The ADD domains of DNMT3 proteins specifically recognise and bind 
histone H3 tails unmethylated at lysine K435-38. In addition, the ADD 
domain mediates the interaction of DNMT3A with numerous 
epigenetic factors and is involved in the allosteric control of DNMT3A 
activity38, 39. The PWWP domains of DNMT3A and DNMT3B are 
essential for the targeting of the enzymes to pericentromeric 
chromatin40, 41 and gene bodies, through specific interaction with 
histone H3 tails trimethylated at lysine 3642-44. The part of DNMT3A 
and DNMT3B located at the very N-terminus is the most variable 
region between both enzymes. It binds DNA45 and is important for 
anchoring of the enzymes to nucleosomes44, 46. However, its specific 
molecular or biological function still awaits elucidation. 
The C-terminal domains of DNMT3A, DNMT3B and DNMT3C share 
~80% sequence identity and contain the catalytic centres of the 
enzymes. They are active in isolated form47. In contrast, despite clear 
homology with the other family members, the C-terminal domain of 
DNMT3L is catalytically inactive due to several amino acid exchanges 
and deletions within the conserved DNA-(cytosine C5)-MTase motifs 
(for general reviews on DNA methyltransferases, cf.8, 19, 48-50). 
B Catalytic properties of DNMTs: processivity and oligomerisation 
All cytosine C5 methyltransferases share similar catalytic 
mechanism and use base flipping to rotate the target base out 
of the DNA duplex and insert it in the catalytic pocket (reviewed 
in51, 52). Since DNA is a long polymer, numerous target sites are 
available for methylation in one substrate molecule. These sites 
can be methylated without dissociation of the enzyme from the 
DNA (processive methylation) or with dissociation of the 
enzyme after each round of binding and methylation 
(distributive methylation). DNMT1 is a highly processive 
enzyme, able to methylate long stretches of hemimethylated 
DNA53-55. This property allows efficient methylation of the newly 
synthetized daughter strand during DNA replication before the 
chromatin is reassembled. The structure of DNMT1 with 
substrate DNA revealed that the enzyme enwraps the DNA, 
enabling sliding of the protein along the substrate and catalysis 
of successive methylation reactions32. Biochemical studies with 
purified DNMT3A and DNMT3B revealed interesting differences 
in the mechanism of both enzymes. DNMT3A was shown to 
methylate DNA in a distributive manner47, 56 and to 
cooperatively bind DNA, forming large multimeric protein/DNA 
filaments57-60. Cooperative binding to substrate DNA allows 
DNMT3A to methylate multiple sites on the same DNA 
molecule, thereby increasing its activity and efficiency61. 
Indeed, a recent study demonstrated that multimerization of 
DNMT3A on the DNA also occurs in cells and allows efficient 
spreading of DNA methylation over a larger region62. Although 
controversial, processive methylation mechanism for DNMT3a 
has also been reported63, but is incompatible with cooperative 
DNA binding. In contrast to DNMT3A, DNMT3B is able to 
methylate multiple CpG sites by a processive mechanism and in 
a non-cooperative manner47, 56. These observations illustrate 
that minor amino acid sequence differences in the catalytic 
domains of DNMT3A and DNMT3B have a profound impact on 
the catalytic mechanism of the enzymes. 
C Intrinsic DNA sequence specificity of DNMTs  
In mammals, DNA methylation is predominantly found within 
CpG dinucleotides. These short palindromic sequences have the 
advantage that both strands of DNA can be modified and 
therefore, after DNA replication, the methylation information 
on the daughter strand can be restored based on the 
methylation information in the parental strand. Re-methylation 
of the DNA in each replication cycle is enabled by the strong 
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preference of DNMT1 towards hemimethylated over 
unmethylated DNA29, 31, 32, 55, 64. Structural studies provided 
molecular explanation for this preference and revealed that the 
methyl group of the cytosine is recognised by a hydrophobic 
pocket in the catalytic domain of DNMT1 and that both the 5mC 
and the corresponding G in the target DNA strand are 
recognized accurately32. This observation also explains the 
specificity of DNMT1 towards CpG sites over non-CpG sites (see 
below). 
In vertebrate genomes, cytosine methylation is thought to be 
largely restricted to CpG sites, for which the inheritance through 
cell division is well established; however, recent studies 
revealed the presence of non-CpG methylation in several cell 
types and tissues, both in mouse and in humans. Still, the 
molecular function, as well as the mechanisms of its 
establishment and maintenance are yet unknown. 
The original DNA methylation pattern is set by DNMT3A and 
DNMT3B enzymes, which are classically regarded as de novo 
MTases, as they can methylate DNA regardless of the DNA 
methylation status at the other DNA strand. Although both 
enzymes methylate cytosine residues preferentially in the 
context of CpG dinucleotides, biochemical studies provided 
evidence that they can also introduce methylation in a non-CpG 
context with an apparent preference for CA >> CT > CC65, 66. In 
addition, knockout of DNMT3 enzymes in ES cells or ectopic 
expression of DNMT3A in Drosophila melanogaster (which lacks 
DNA methylation) provided direct evidence that DNMT3 
proteins can introduce methylation in non-CpG context also in 
vivo67. Interestingly, the methylation rates of DNMT3 enzymes 
at non-CpG sites can be as high as half of the rates at CpG sites65-
67 and the non-CpG methylation reaches levels similar to that of 
mCpG in some human cells68, 69. In contrast, the non-CpG 
methylation rates of DNMT1 are very low29, 31, indicating that 
non-CpG methylation cannot be propagated by DNMT1 and 
would be lost through cellular division in the absence of DNMT3 
enzymes. Therefore, non-CpG methylation can serve as a direct 
imprint of DNMT3 enzyme expression or/and activity in the 
cells. Consistently, methylated non-CpG sites are widespread in 
embryonic stem cells, induced pluripotent cells, oocytes and 
postnatal brain, where DNMT3A and DNMT3B are highly 
expressed, but absent in most somatic tissues and in cells with 
low expression of these enzymes68-72. Unexpectedly, a recent 
deep-sequencing survey of 18 human tissues revealed presence 
of methylation at non-CpG methylation in almost all tissues73, 
indicating that DNMT3 activity is widespread and contributes to 
the overall DNA methylation patterns.  
These observations raised important questions regarding the 
functional relevance of non-CpG methylation. It has been 
considered a by-product of the hyperactivity and low specificity 
of DNMT3 enzymes10, 70. Depending on the experimental 
system, there is evidence of its potential role in gene 
repression69, 74, 75, but also in gene expression 76. Most insights 
about the potential role of non-CpG methylation came from 
studies on brain (reviewed in76, 77), where non-CpG methylation 
occurs at high levels and contributes to neuronal maturation 
and specification of brain cells, processes crucial for brain 
development68. First insights into the mechanistic 
understanding of non-CpG methylation signalling were 
provided recently with the observation that non-CpG 
methylation can recruit MeCP269, 78, 79, an important epigenetic 
factor, mutation of which leads to Rett syndrome in humans, 
and that this process contributes to the repression of long genes 
in the brain78. However, further studies are required to 
elucidate the exact biological function of the non-CpG 
methylation. 
C Flanking sequence preferences 
Although in comparison to prokaryotic methyltransferases 
DNMT3A and DNMT3B do not seem to have strong sequence 
specificity beyond CpG sites, both enzymes are very sensitive to 
the sequences flanking their target sites. DNMT3A prefers 
purine bases at the 5’ end of the CpG sites, whereas pyrimidines 
are favoured at their 3’ end80-82. These so called flanking 
sequence preferences of the methyltransferases might have 
strong impact on the generation of methylation patterns, as 
CpG sites embedded unfavourable flanking sequence context 
cannot be methylated by DNMT3A at all81. Interestingly, 
experimental flanking sequence preferences of DNMT3A and 
DNMT3B correlate with the statistical data on the methylation 
level of CpG sites found in the human genome80, 83, suggesting 
that the inherent sequence preferences of de novo enzymes 
contribute to the selection of genomic regions that undergo 
methylation.  
Since both DNA strands of a CpG site are embedded in different 
flanking sequence context, they will vary strongly in the ability 
to undergo methylation by DNMT3. This leads to the 
preferential methylation of one strand, generating 
hemimethylated products. Consistently, the presence of 
hemimethylated sites was demonstrated in ES cells84. As 
hemimethylated sites are preferred substrates for DNMT1, the 
cooperation of both enzymes might promote efficient de novo 
methylation of unmethylated DNA85. The exact mechanistic 
understanding of the flanking sequence preferences and 
specificity of DNMT3 awaits availability of the structure with 
bound substrate DNA. 
B Genome-wide distribution of DNA methylation 
Rapid development of the next-generation-based deep 
sequencing technologies enabled genome-wide interrogation 
of cytosine methylation at single-base resolution. First 
comprehensive methylome maps provided invaluable insights 
into the frequency and genomic distribution of 5mCs, as well as 
into the interplay between DNA methylation and other 
epigenetic mechanisms72, 86, 87. In addition, global methylation 
maps of early developmental stages, germ line development 
and differentiation of progenitor cells shed lights into the 
dynamics of DNA methylation during global reprogramming and 
cellular specialization (reviewed in10, 88-90). 
DNA methylation occurs predominantly in the context of CpG 
sites and decorates most of the cytosines (70-80%) throughout 
the entire human genome. However, methylated CpGs are not 
equally distributed in the genome10, 91. Most methylation is 
found in repetitive sequences, gene bodies and intergenic 
regions72, 92, 93. In turn, CpG islands (CGI), which are regions of 
higher than expected density of CpG sites, are mostly 
unmethylated, especially when located in promoters of active 
genes94-96. Conversely, CpG-poor promoters are usually 
methylated when not active. While CGIs are found throughout 
the genome, they are often associated with promoter regions; 
with around 60% of annotated genes having CGI related 
promoters97, 98. Only a fraction of CGI promoters that control 
imprinted and tissue-specific genes become methylated10, 99. 
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Similarly, distal regulatory regions, encompassing enhancers, 
display reduced levels of DNA methylation when they are active 
and occupied by transcription factors91, 100, 101. The greatest 
variation in DNA methylation across different cell types is 
thought to occur in regions located near CpG islands (within 2 
kb), termed CpG shores that acquire tissue- and disease- 
specific methylation changes102. Interestingly, a new feature has 
been added to the human epigenetic landscape with 
identification of very large regions with low average 
methylation, called methylation canyons103 or methylation 
valleys104. These domains include highly conserved, 
developmentally important genes that might be associated with 
cancer103. 
B Recruitment of DNMT enzymes 
Despite more than two decades of intensive research on the 
targeting and regulation of DNA methyltransferases in cells, the 
major question in the field, namely, understanding how specific 
DNA methylation patterns are established, remains only 
partially answered. Several synergistic models have been 
proposed, including both the inherent properties of DNMT 
enzymes, as well as the contribution of other epigenetic marks 
and protein partners (Figure 3). The most important ones will 
be summarised below. 
C Recruitment of DNMT3s by chromatin marks 
Direct recognition of specific chromatin marks has been 
proposed as a general mechanism involved in the recruitment 
of DNA methyltransferases to specific genomic regions. All 
DNMT3 proteins possess specific domains in their N-termini 
(ADD domain and PWWP domain) that directly sense the 
modification state of histone H3 tail in chromatin and could 
therefore recruit the MTases to the nucleosomes containing 
unmethylated H3K4 and (or) trimethylated H3K36. Through 
their ADD domains, DNMT3 proteins interact specifically with 
H3 tails unmethylated at K4 and this interaction is blocked by 
the methylation of K4 (H3K4me3)36, 37, 105, 106. Interestingly, 
binding to H3 tails allosterically activates DNMT3A38, 39 and 
stimulates methylation of chromatin-bound DNA by DNMT3A in 
vitro106. Because methylation of H3 at K4 is associated with 
active genes, the lack of this modification in specific regions 
could be interpreted as a signal for their inactivation, whereas 
its presence would consequently repel DNA 
methyltransferases. Several genome-wide studies support this 
hypothesis, as strong inverse correlation of DNA methylation 
and H3K4me3 modification was observed83, 86, 94, 107. This 
targeting mechanism was provided recently by two elegant 
studies. Morselli and colleagues showed that the introduction 
of DNMT3B in yeast cells, which lack DNA methylation, leads to 
the generation of methylation in regions devoid of H3K4me3108. 
Finally, engineering of the ADD domain of DNMT3A led to 
aberrant DNA methylation patterns in cells105, directly 
demonstrating the crucial role of this domain in enzyme 
targeting. 
Specific recognition of H3 tails tri-methylated at K36 
(H3K36me3) is mediated by the PWWP domains of DNMT3A 
and DNMT3B. As in the case of ADD domain-H3 interaction, 
several lines of evidence support a model, in which PWWP-
H3K36me3 interaction might directly contribute to the 
recruitment of DNMT3 enzymes to specific genomic regions, 
including gene bodies and pericentromeric chromatin. 
Accumulation of H3K36me3 and DNA methylation, and their 
strong correlation was observed in euchromatin in the body of 
active genes and at exon-intron boundaries, with exons showing 
increased levels of both marks44, 92, 93, 107, 109-113. Functional role 
of gene body methylation has been revealed recently by an 
elegant study, which showed that H3K36me3-dependent 
intragenic DNA methylation by DNMT3B protects the gene 
bodies from spurious RNA polymerase II entry and cryptic 
transcription initiation42. Furthermore, a subset of 
heterochromatic repeats is strongly enriched in H3K36me3114, 
which can explain the role of the DNMT3A PWWP domain in the 
heterochromatic localization of the enzyme40, 41. The central 
role of H3K36me3 recognition in targeting of DNA methylation 
has also been recently experimentally confirmed in a variety of 
cellular systems42, 44, 108. In addition to H3 binding, the PWWP 
domains of DNMT3A and DNMT3B interact with DNA115, 116. 
Recently, a model for methylation of nucleosomal DNA by 
DNMT3A has been proposed117. It suggested that the targeting 
of DNMT3A occurs through a specific binding of H3K36me3 by 
the PWWP domain, which is followed by an activation of the 
catalytic domain through the binding of H3 tails unmodified at 
K4 to the ADD domain, resulting in the methylation of nearby 
cytosines.  
The general picture that emerges from all these observations is 
that the multivalent interaction of the DNMT3 enzymes with 
chromatin plays a crucial role in the generation of the genomic 
DNA methylation pattern.  
C Recruitment of DNMT1 to replicating chromatin 
Several targeting mechanisms contribute to the proper 
localization of DNMT1 to replicating DNA. The main ones 
involve PCNA and UHRF1. PCNA, a component of the replication 
machinery, interacts and co-localizes with DNMT1 in vivo118, 
indicating that it might recruit the methyltransferase to the 
replication fork and load it onto DNA. This interaction 
contributes to the efficiency of DNA re- methylation, but it is not 
essential for this process23. UHRF1 is an epigenetic factor 
essential for the maintenance of DNA methylation patterns in 
mammals, as emphasized by the phenotype of UHRF1 
knockout119, 120. UHRF1 specifically binds to hemimethylated 
DNA via its SRA domain120-123 and recognizes the N-terminal tails 
of histone H3 di- and tri-methylated at lysine 9 (H3K9me2/me3) 
via combined binding of its tandem Tudor domain (TTD) and its 
plant homeodomain (PHD)124-127. These specific chromatin 
interactions of UHRF1 are necessary for the recruitment of 
DNMT1 to replicating chromatin and DNA methylation 
maintenance, since mutations preventing histone binding in any 
of the domains abolished DNA methylation by DNMT1 in 
cells125, 127, 128. In addition to its role in targeting of DNMT1, 
UHRF1 was also shown to stimulate the catalytic activity of 
DNMT1 through direct interaction129, 130. 
First evidence for direct binding of histone marks by DNMT1 has 
been provided with the observation that the methyltransferase 
preferentially associates with H3 tails ubiquitinated at K18 and 
K23131, 132. This interaction is mediated by the replication foci-
targeting domain of DNMT1 and leads to the activation of the 
enzyme and its recruitment to newly replicated DNA. The 
ubiquitination of the H3 tail is introduced by the RING domain 
of UHRF1 and is stimulated by UHRF1 binding to 
hemimethylated DNA133. Ubiquitinated H3 accumulates during 
S-phase, behind replicating DNA polymerase, leading to DNMT1 
recruitment to newly replicated DNA131-133. These data indicate 
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an important additional connection between DNMT1 and 
UHRF1 chromatin interactions, which is essential for an efficient 
recruitment of DNMT1 and maintenance methylation. 
A Removing DNA methylation 
For decades, 5mC was considered as a stable modification, due 
to the chemical nature of the C-C bond, therefore DNA 
demethylation was believed to occur through replication-
dependent dilution due to the absence or inhibition of the 
maintenance methylation machinery. This notion changed in 
the year 2000, when global loss of the methylation mark was 
detected in mouse zygotes, in a manner independent of DNA 
replication134, 135. During mammalian development DNA 
demethylation was observed at two stages. The first wave of 
demethylation occurs during early embryogenesis in the 
paternal genome, following fertilization and preceding DNA 
replication and confers totipotency to the developing embryo. 
DNA methylation pattern is then re-established in the 
preimplantation stages134, 135. The second occurrence is during 
the germ cell specification that includes demethylation of 
imprinting genes136, 137. Furthermore, active DNA 
demethylation has also been observed at specific loci in T cells, 
neurons and other cells138, 139.  
Despite the discovery of biological processes where DNA 
demethylation occurs in the absence of DNA replication, 
enzymatic machinery and molecular explanation of the 
demethylation process was at least controversial and spoiled by 
lack of reproducibility of the findings by independent 
laboratories (reviewed in140). Initial reports on the involvement 
of base excision repair (BER) in excising 5mC in chicken 
embryos141 and the demonstration of DNA demethylation 
through direct excision of the methyl group containing base by 
the DEMETER/ROS1 family of DNA glycosylases in plants had 
raised the possibility of the presence of similar pathways in 
mammals (reviewed in142). However, the search for an 
orthologous glycosylase, which could excise the methyl group in 
mammals, was not fruitful, as the enzymes suspected to have 
the glycosylase activity on 5mC, such as TDG and MBD4, had a 
stronger activity on T/G mismatch repair and around a 30-40 
fold weaker activity on 5mC in vitro than on T:G mismatches143, 
144. Thus, the enzyme responsible for active DNA demethylation 
in mammals remained enigmatic for a long time. A major 
breakthrough came in 2009, when a group of enzymes called 
Ten-Eleven Translocation (TET) was shown to oxidize 5mC to 5-
hydroxymethylcytosine (5hmC) both in vitro and in mES cells, in 
which 5hmC constitutes about 0.03% of total nucleotides145. In 
parallel, an independent group identified the presence of higher 
levels of 5hmC (about 0.6% and 0.2% of total nucleotides) in 
mouse Purkinje neurons and granule cells respectively146. These 
two seminal discoveries uncovered a possible pathway for 
active DNA demethylation and give rise to a new dynamic field 
of research. 
B Mammalian TET enzymes 
Although the gene coding for TET1 (also known as CXXC6) was 
known to be a fusion partner of MLL involved in acute myeloid 
leukaemia (AML)147, its function was not characterized until 
2009. The catalytic activity of TET enzymes was first predicted 
based on the computational search for DNA modifying enzymes 
using as bait the sequence of the dioxygenase domain of JBP1 
and JBP2, which oxidize the methyl group of thymine to 5-
hydroxymethyluracil in trypanosomes148, 149. The TET enzymes 
belong to the iron and α-ketoglutarate dependent dioxygenase 
family (Fe2+/αKG-DO). Bioinformatics searches further 
revealed that TET enzymes are distributed across the 
metazoans that have DNA methylation marks and are also 
present in fungi and algae148. 
The oxidized base 5hmC was first described in 1952, when it was 
identified in the genomes of T-even bacteriophages (T2 and T4) 
as a modified base, which gets further glucosylated and 
provides protection against cleavage by bacterial restriction 
enzymes150. Later, Penn and colleagues demonstrated that 
5hmC was also found in adult rats, mice and frogs and that it 
accounted for ~ 15% of total cytosines151. Yet this finding was 
disregarded by the scientific community, as it could not be 
reproduced by another group152. Thereafter, the formation of 
5hmC in mammalian cells was thought to result from oxidative 
damage until its rediscovery in 2009. Later studies showed that 
5hmC is present in different mouse tissues, such as heart, 
kidney, lung, muscle and the highest level is found in the brain 
and ES cells153. 
Furthermore, it was demonstrated that similarly like in the 
thymidine salvage pathway (Smiley et al. 2005), TET enzymes 
can further oxidize 5hmC to 5-formylcytosine (5fC) and 5-
carboxylcytosine (5caC)154, 155 and that these higher oxidized 
bases (5fC and 5caC) are recognized and excised by the thymine 
DNA glycosylase (TDG), which trigger the base excision repair 
pathway (BER) to replace the abasic site by an unmodified 
cytosine154, thereby completing the DNA demethylation 
pathway (Figure 2). 
B Structural organization of TET enzymes 
The mammalian TET family comprises three members that 
share similar domain architecture, namely, TET1, TET2 and TET3 
(Figure 1). These are large proteins harbouring the catalytic 
domain at their C-terminus, which is composed of a double-
stranded β helix domain (DSBH) characteristic for Fe2+/αKG 
dioxygenases and a cysteine-rich region preceding the DSBH. In 
metazoan TETs, the DSBH is interrupted by a large unstructured 
region, which is less conserved than the DSBH domain and is 
believed to engage in protein-protein interactions. Both TET1 
and TET3 contain a CXXC domain at their amino terminus. The 
TET2 protein lacks the CXXC domain, which was lost during 
evolution after gene duplication and inversion, and is now 
coded as separate protein IDAX (inhibition of the dvl and axin 
complex)148, 156.  
The core catalytic domain (DSBH) forms the characteristics 
dioxygenase domain and contains the binding sites for Fe2+ and 
αKG, which are both essential for the catalytic activity. The 
amino acids that are crucial for Fe2+ and αKG binding in the 
DSBH and Zn2+ binding in the Cys-rich domain are conserved 
among the family members and all the three enzymes are 
shown to be catalytically active in vitro145, 148 and in vivo155.  
The crystal structure of the human TET2 catalytic domain and 
nTet (TET homolog from an amoeboflagellate Naegleria 
gruberi) was solved recently157, 158. The structure of the TET2 
catalytic domain (PDB ID: 4NM6) in complex with 5mC 
containing DNA revealed that the catalytic domain containing a 
DSBH core forms a globular structure, which is stabilized by the 
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flanking region of DSBH and the Cys-rich region. Unlike the Cys-
rich region in other proteins, in TET this region does not form an 
independent domain, but wraps around the DSBH core 
stabilizing the overall structure of the enzyme and are crucial 
for catalysis158. DNA is bound above the DSBH core, which is 
enriched in basic and hydrophobic amino acids. Similar to DNA 
MTases and DNA repair enzymes159, 160, TET enzymes utilize a 
base flipping mechanism to position the target base in the 
catalytic pocket for the oxidation reaction. Once the methyl 
group is located in the catalytic pocket, it is oriented towards 
the catalytic iron and α-KG, which facilitate the catalytic 
turnover157, 158. 
Analysis of the interaction of human TET2 with DNA 
indicates that besides the target 5mC within a CpG dinucleotide 
context, the enzyme does not interact with the bases flanking 
the CpG site158. Intriguingly, the enzyme also does not make 
contact with the methyl group of the target cytosine, suggesting 
that this would allow TET2 to generate higher oxidation of 5hmC 
to 5fC and 5caC158. Additionally, TET enzymes have been shown 
to oxidize the methyl group of thymine (T) to 5-hydroxymethyl 
uracil (5hmU)161, however the physiological relevance still 
needs to be uncovered. 
B TET-mediated DNA demethylation pathways 
Identification of TET enzymes and their reaction products has 
paved the way for DNA demethylation through a direct 
enzymatic action on the methyl groups. Since their discovery, 
numerous plausible DNA demethylation pathways involving 
TETs have been investigated, both in vivo and in vitro. 
Intriguingly, the formation of 5hmC via TET enzymes was shown 
to facilitate the passive dilution of modified bases, as DNMT1 is 
less active on hemi-5hmC containing DNA (> 60-fold) in vitro162, 
163. This contributes to the replication-dependent loss of 
methylation induced by 5hmC formation. However, this 
observation has been challenged by recent reports. In vitro 
studies showed that the DNMT1 interaction partner UHRF1 
binds 5hmC164-166 thereby targeting DNMT1 to hemi-5hmC 
containing DNA. Secondly, unlike DNMT1, DNMT3A and 
DNMT3B are not sensitive to hemi-5hmC DNA and can re-
methylate hemi-5hmC containing DNA162, 167. These 
observations argue against 5hmC-mediated passive dilution and 
require further investigation. 
The other suggested pathway involves TET-TDG-BER mediated 
DNA demethylation, where the higher oxidation products 5fC 
and 5caC generated by TET enzymes are excised by TDG, 
followed by the generation of an abasic site and lesion repair 
with an unmodified cytosine by the BER machinery 154, 155. 
Accumulated evidence suggested that this is the main DNA 
demethylation pathway triggered by TET enzymes168. This is 
supported by the observations that the knockdown of TDG in 
mES cells results in an up to 10-fold increase of 5fC and 5caC169, 
170, whereas the overexpression of TDG leads to the opposite 
effect with no significant changes in the level of 5mC or 
5hmC171. Moreover, in vitro investigation of TDG demonstrated 
that TDG removes 5fC and 5caC in CpG dinucleotide context 
more efficiently than the mismatch repair T:G172, 173, suggesting 
that the main function of TDG is the excision of the oxidized 
bases over T:G removal. Nevertheless, TDG-BER mediated 
demethylation cannot account for the genome-wide 
demethylation, as TDG is not highly expressed in the zygote and 
loss of TDG does not affect the demethylation in zygote174. 
Furthermore, TDG and the BER mechanism may compromise 
the genome stability by introducing multiple nicks and single or 
double strand breaks in the DNA, while processing multiple 
methylation sites on the DNA molecule. This indicates that 
either other DNA glycosylases are involved in this process or 
other TET-independent demethylation mechanisms are 
responsible for the majority of observed demethylation175. 
Besides BER, nucleotide excision repair (NER) protein GADD45A 
has also been implicated in DNA demethylation and it was 
shown to interact with TET176-178. These observations suggest 
that both NER and BER may cooperate with TET enzymes in 
processing the oxidized base, but further experimental 
evidence is needed. 
Another possible demethylation pathway involves the 
AID/APOBEC mediated deamination of 5hmC to 5hmU, which is 
removed by DNA glycosylases such as SMUG, MBD4, NEIL or 
TDG170, 179, 180. Supporting this view, a study conducted in the 
mouse brain (which has the highest level of 5hmC) reported 
that TET-mediated formation of 5hmC could be processed 
further to 5hmU by AID/APOBEC. Moreover, both enzymes 
work synergistically at the locus specific DNA demethylation of 
neuronal activity induced genes in mouse dentate gyrus181. 
Alternatively, the capacity of TET enzymes to oxidize thymine to 
5hmU was shown to trigger DNA demethylation through DNA 
glycosylases and BER161. However, this pathway of DNA 
demethylation still remains controversial due to the 
inconsistencies in the reported results and needs to be clarified 
in further studies.  
Another very elegant and biochemically plausible 
demethylation pathway that has been proposed involves direct 
removal of the carboxyl group from 5caC by a putative 5caC 
decarboxylase. This hypothetical enzyme should work similarly 
to orotate decarboxylase, as observed in the thymidine salvage 
pathway182, which very efficiently catalyzes the loss of carboxyl 
group linked to C6 of the pyrimidine ring. However, despite 
intensive effort of multiple research groups, no such 
decarboxylase specific for 5caC has been identified so far in 
mammals.  
Interestingly, DNA demethylation involving both DNMTs and 
TETs has also been observed in vitro. In the absence of AdoMet, 
the methyltransferase DNMT1 was shown to remove 5hmC as 
formaldehyde183 and a similar result was shown for DNMT3A 
and DNMT3B, however it required non-physiological 
concentration of H2O2184. Moreover, DNMT3A was reported to 
convert 5caC to C in the absence of AdoMet185. It should be 
noted that these conclusions were drawn based on in vitro 
experiments and need to be validated in vivo. In addition, such 
activity in vivo would require prevention of the AdoMet binding 
by the methyltransferase, which could occur through a post-
translational modification of the enzyme that would block the 
binding site.  
B Recruitment of TET enzymes 
Despite a recent progress in understanding the physiological 
relevance of TET enzymes and their reaction products, there is 
a rather limited progress in understanding of the mechanisms 
of recruitment and regulation of TET enzymes. The presence of 
the CXXC domain on the N-terminus of TET1 and TET3 is 
believed to be partly responsible for targeting of these enzymes 
to the CpG containing regions, as the CXXC domain has been 
shown to recruit DNMT1, MLL1, CFP1 to unmethylated CpG 
sites186, 187. Consistently, DNA binding studies showed that TET1 
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is able to bind to CpG-rich DNA irrespective of its modification 
state (C, 5mC or 5hmC)188, 189, whereas the Xenopus TET3-CXXC 
domain binds unmodified C in both CpG and non-CpG context, 
with a slightly higher preference for CpG190, 191. Another 
interesting study demonstrated that CXXC domain of TET3 can 
bind 5caCpG and that TET3-FL preferentially binds to the TSS of 
genes involved in base excision repair mechanism191. This 
suggests that TET3 may be specifically targeted to these loci 
through the CXXC domain or by other interacting proteins191 
and oxidize 5mC at these transcriptional start sites (TSSs). 
Unlike TET1 and TET3, TET2 lacks the CXXC domain and may 
depend on other proteins or TFs for locus specific recruitment. 
Supporting this idea, TET2 has been shown to interact with the 
transcription factor Wilms tumor (WT) and Early B cell factor 1 
(EBF1) which modulate the TET2 activity and target gene 
expression192-194. 
Likewise, NANOG-dependent recruitment of TET1 and TET2 has 
also been suggested to promote expression of genes involved in 
reprogramming and lineage commitment195. Furthermore, a 
study by Perera and colleagues in mouse retinal cells 
demonstrated that RE1-silencing transcription factor (REST) 
recruits a TET3 isoform lacking the CXXC domain, which then 
interact with the histone methyltransferase NSD3 and activates 
its target genes196. TET enzymes were shown to interact with 
proteins involved in base excision repair pathway such as TDG, 
PARP1, MBD4, NEIL etc197. Furthermore, all three TET enzymes 
are reported to associate with O-linked ß-D-N-
acetylglucosamine (O-GlcNAc) transferse (OGT). It has been 
suggested that TETs recruit OGT to the chromatin and that TET-
OGT interaction promotes the OGT activity198-200. In summary, it 
is increasingly clear that TET enzymes do not function alone, and 
they interact with multiple other proteins in a contextual 
manner and through this cooperation modulate gene 
expression. 
B Genome-wide distribution of TETs and their reaction 
products 
Initial quantification of the level of 5hmC has revealed that it is 
detectable in most of the tissue tested. However, unlike 5mC, 
level of which is relatively constant across different somatic 
cells constituting ~4% of total cytosines201, the level of 5hmC is 
lower than of 5mC and varies between different tissue types. It 
is most abundant in ES cells and in brain, where it constitutes 
between 0.4 and 0.7% of total cytosines, and present at lower 
levels in other tissues146, 202-205. Interestingly, cancer cells often 
contain lower levels of 5hmC than the surrounding 
untransformed tissues, which has become a hallmark of certain 
types of cancers, for example, melanoma206. 
In contrast to 5hmC, initial attempts to quantify the levels of 5fC 
and 5caC were unsuccessful due to their very low abundance as 
they are rapidly excised from the DNA. However, development 
of more sensitive techniques has enabled quantifying the levels 
of the oxidized bases, showing that they are 10-100 fold less 
abundant than 5hmC (0.02-0.002%)207, 208. Interestingly, despite 
their low abundance (especially of 5fC), both 5hmC and 5fC 
could be detected after several cell divisions208, 209, suggesting 
that they might be stable marks.  
Genome-wide studies showed that in both ES cells and in brain 
tissues, 5hmC is enriched in euchromatic regions, especially at 
the transcriptional start sites (TSSs), moderate and low CG 
content promoters, and gene bodies189, 210-215. 5hmC on gene 
bodies is positively correlated with gene expression in both 
brain and ES cells213. In ES cells, 5hmC is mostly prevalent in 
developmentally regulated genes marked with bivalency (PRC2 
target gene), TF binding regions, active enhancers and CTCF 
binding sites, but not on housekeeping genes212, 216, 217, whereas 
in brain, 5hmC is present in higher levels on poised enhancers 
primed for activation than on active enhancers218. The overall 
level of 5hmC observed around TSSs and gene promoters in 
neuronal cells are lower compared to ES cells210, 213, 219, 
indicating that 5hmC in somatic cells has cell type specific roles.  
Similar to 5hmC, in ES cells 5fC is enriched at CpG island (CGI) 
containing promoters, TSSs (marked with H3K4me3), exons and 
gene regulatory elements, especially at the poised enhancers 
169, 220, 221. However, 5fC is enriched at exons and enhancers of 
actively expressed genes in a tissue type specific fashion222, 223. 
Interestingly, 5fC-enriched sites show increased binding of 
p300220 and 5fC containing promoters are positively correlated 
to gene expression169, indicating that the 5fC mark can recruit 
chromatin factors and may exhibit a distinct regulatory 
function. 
Genome-wide mapping of TET1 occupancy showed that there is 
a significant overlap between the co-occurrence of both 5hmC 
and TET1 in the genome. In ES cells, TET1 is localised in 60% of 
bivalent genes and on the promoters of PRC2 occupied genes 
carrying H3K27me3, but not on the promoters harbouring 
H3K4me3 alone211, 224. TET1 is present on GC-rich promoters 
with intermediate and low CpG content (like NANOG, ESRRB, 
TCL1, KLF4223), but not with high CpG density 189. This suggests 
that TET1 regulates both the developmentally regulated genes 
and the TFs inducing pluripotency225. TET enzymes also co-
localise with Sin3A independent of 5hmC212.  
B TET intrinsic DNA sequence specificity 
Most of the studies on TET enzymes were focused on 
elucidating their biological role and their reaction products; 
however, the intrinsic biochemical properties of TET enzymes 
that govern their function remain not well understood. In 
particular, little is known about how TET enzymes choose the 
target sequence. Do TET enzymes exhibit any flanking sequence 
preference (in the context of CpG sites)? How specific are they 
towards CpG sites? Do they show preference for oxidation of 
different modified base (5mC, 5hmC and 5fC)? How do they 
catalyse the stepwise oxidation on one site (5mC to 5caC) and 
how do they oxidize multiple 5mC (also 5hmC or 5fC) substrates 
on a single DNA strand (from one 5mC/5hmC/5fC substrate to 
another), in a distributive or in a processive manner?  
Although the solved crystal structures of hTET2-CD and nTet in 
complex with DNA (both 5mC and 5hmC) provided some insight 
into the behaviour of TET enzymes157, 158, 226, detailed 
biochemical evidence is still lacking. This is especially important 
considering recent reports showing that TET-dependent 
demethylation in zygotes represents only a small fraction of all 
demethylation events observed174, 175 and that TET-associated 
demethylation seems to be locus specific, suggesting potential 
more stringent sequence preference than the ubiquitous CpGs. 
Interestingly, fine mapping of 5hmC genomic locations using 
SCL-exo protocol showed that 5hmC is not randomly 
distributed, but rather highly enriched within defined sequence 
context227. It is still unknown what is the molecular reason 
granting this sequence preference.  
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C CpG vs non-CpG hydroxymethylation 
Both DNMTs and TET enzymes recognize and modify CpG 
dinucleotides, yet DNMT3 enzymes were shown to efficiently 
modify non-CpG sites. Surprisingly, little work was contributed 
to investigate the intrinsic preference of TET enzymes towards 
non-CpG sites. In the initial report that identified TET enzymes 
as 5mC hydroxylases, the authors showed that TET enzymes are 
capable of oxidation of 5mC embedded in a CpG site, yet non-
CpG substrates were not tested. Hu and colleagues used three 
DNA duplexes containing single 5mCpX sites and showed that 
5mCpA and 5mCpC sites were poor substrates for TET, with 
conversion efficiencies of <2% and <5%, respectively, as 
opposed to >85% for 5mCG sites in the same sequence 
context158. Another report using a different experimental 
approach came to a similar conclusion228. These authors used a 
library of dsDNA substrates where 5mC was embedded in 
randomized sequence context, treated DNA in vitro with TET1, 
enriched the converted, 5hmC-containing products with an 
anti-5hmC specific antibody and analysed with high-throughput 
sequencing. Similarly as TET2, the TET1 was shown to 
preferentially oxidize 5mCpG with some incidence of oxidation 
of 5mCpC sites. 
B Processive oxidation on the site and lateral processivity 
Processivity of TET enzymes can be regarded in two different 
means, first “on site processivity” is the serial oxidation of 5mC 
to 5hmC, 5fC and 5caC on a single CpG site without the enzyme 
dissociating from the site and second is the consecutive 
oxidation of numerous CpGs on a single DNA molecule, which 
could be called “lateral processivity”. The group of Yanhui Xu 
reported that the catalytic domain of human TET2 efficiently 
oxidizes 5mC to 5hmC, but the further oxidations are inefficient 
leading to stalling of the reaction at the 5hmC state226. 
However, the same group reported before that the TET2 could 
convert 5mC all the way to 5caC158. Numerous reports from 
other groups also showed that TET enzymes are capable to 
efficiently convert 5mC to 5caC229-231. Surprisingly, the two 
studies that investigated the mouse TET2 “on site” processivity 
came to contradictory conclusions, which could potentially be 
explained by differences in the reaction conditions and 
experimental setup229, 231.  
An unexpected discovery that TET3 CXXC preferentially binds 
5caCpG led to proposition that this interaction can stimulate 
processive activity of the enzyme leading to spreading of the 
5caC from the first oxidized CpG site. In the proposed model, 
the first 5mCpG site that is oxidized to 5caCpG gets bound by 
the CXXC domain of the enzyme, therefore keeping the catalytic 
domain in close proximity and promoting oxidation of nearby 
5mCpGs191. It is a very interesting hypothesis, which still 
requires experimental proof. 
C Flanking sequence preference 
The non-random distribution of 5hmC as discussed above 
suggests that TET enzymes can have a more stringent sequence 
preference and/or be targeted to these locations by other 
protein factors. In the TET2/DNA co-crystal structure no 
protein-base specific contacts outside of the CpG site were 
observed, suggesting that the enzyme has weak or no flanking 
sequence specificity158, 226. Nevertheless, one can note that the 
bound DNA is strongly bent and distorted, giving the possibility 
of indirect readout of DNA sequence as observed with 
numerous other DNA binding proteins, restriction enzymes and 
bacterial MTases232, 233. Whether TET enzymes use indirect 
readout for sequence recognition still remains to be addressed. 
Perspectives 
DNA methylation contributes an important mechanism to 
epigenetic regulation of cellular differentiation. Intensive 
research of the past 2 decades elucidated the distribution of 
DNA methylation in human genome, as well as contributed to 
the understanding of molecular mechanisms involved in DNA 
methylation pattern establishment and maintenance. 
Important mechanisms responsible for the recruitment of the 
DNA methyltransferases to specific genomic regions have been 
identified, including interaction of DNMTs with modified 
histone marks, as well contribution of inherent properties of the 
MTases, like sequence preference, processivity or 
oligomerisation (Figure 3).  
Considering its role in epigenetic inheritance, DNA CpG 
methylation has traditionally been considered as a very stable 
mark that could only be lost via its dilution over several 
replication cycles in the absence of the maintenance 
methyltransferase activity. This paradigm was challenged by 
multiple observations of active demethylation events occurring 
independently from DNA replication. After the discovery of TET 
enzymes and elucidation of enzymatic activities contributing to 
further processing of the 5mC intermediates, the methylation-
demethylation cycle has been closed. With the follow up 
genetic and functional studies it become increasingly clear that 
active DNA demethylation, conferring reversibility of DNA 
methylation pattern, contributes an important mechanism to 
the epigenetic regulation. Based on the seminal research of the 
past decade, novel view emerges, in which a delicate balance of 
ongoing methylation and demethylation shapes final epigenetic 
methylation pattern of the cell. Despite the considerable 
progress in understanding how cell type specific DNA 
methylation patterns are established and maintained we are 
still far from understanding a complete picture.  
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